India’s food safety regulator has moved from warning to formal action against Nestle India over how infant formula products are marketed. The Food Safety and Standards Authority of India (FSSAI) is initiating legal adjudication against Nestle India over promotional claims for NAN EXELA Pro Stage 1 and Lactogen Pro 1 under the Infant Milk Substitutes (IMS) Act.
This is a significant development for brand teams because the IMS Act is not a general advertising code. It is a deliberately protective legal framework designed to prevent the promotion of breastmilk substitutes and, by extension, to safeguard breastfeeding practices.
What is being examined
The regulator has not publicly detailed the exact promotional claims under scrutiny. What is clear is that the action involves early-stage infant formula products. That places the case in one of the most tightly controlled marketing categories in India’s food sector.
Under the IMS Act, advertising and promotion of infant milk substitutes are heavily restricted. Companies are expected to provide factual information without creating a promotional appeal that could discourage breastfeeding or mislead caregivers.
Why this matters for marketing teams
For marketing professionals, the case is a reminder that health-related categories do not operate on the same creative playbook as mainstream consumer goods. A product description, packaging statement or digital listing that would be acceptable for a general food brand can become a compliance risk in infant nutrition.
There are three immediate implications for brand and content teams:
- Regulatory review must start with the brief, not end with the launch. Category-specific rules such as the IMS Act should shape messaging decisions early.
- Promotion is not limited to paid ads. Product pages, e-commerce descriptions, influencer briefs and trade communication all count.
- Risk is not just financial. For baby care brands, a regulatory dispute can affect trust among parents and caregivers.
A framework for regulated categories
When marketing products such as infant formula, teams can use a simple check: does the statement inform a caregiver, or does it persuade? In this category, persuasion is the regulatory fault line. If the language reads like advertising rather than factual guidance, it is likely to attract scrutiny.
Companies should document how claims are substantiated and ensure that packaging, digital content and retailer assets use consistent, legally approved language.
What to watch next
The adjudication process will reveal more about which formats FSSAI considers problematic. The outcome may create a reference point for how infant nutrition brands across India frame product benefits, especially in digital channels where content is updated frequently and often without legal review.
For now, the central message is clear: in sensitive health categories, marketing language is compliance language first.
Source: India Today
